HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.
COVID-19 Vaccine Development
- Biopharmaceutical Development on COVID:19
COVID-19 vaccine development has facilitated through unparalleled collaboration in the pharmaceutical industry and between governments. The geographic distribution of COVID-19 vaccine development puts North American entities having about 40% of the activity compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa
The safety requirements for COVID-19 vaccines are the same as for any other vaccine and will not be lowered in the context of the pandemic. After development, the vaccines will continue to be carefully monitored for safety and effectiveness
PDDS 2022 Speakers
Victoria Demina
NEUWAY Pharma GmbH, GermanySubmit your abstract Today
Title : Drug Delivery to the Brain using Engineered Protein Capsules (EnPCs®)
Victoria Demina, NEUWAY Pharma GmbH, Germany
Title : NEWER ADVANCES OF ANTI –HIV THERAPY
Bhuvanesh baniya, Jai Narain Vyas University Jodhpur, India
Title : Insulin Resistance Associated Alzheimer Disease Condition in Rats is ameliorated via Epigenetic Regulation and Autophagy Modulation
Violina Kakoty, Birla Institute of Technology and Science-Pilani, India
Title : SELF MICROEMULSIFYING SYSTEMS BASED TOPICAL LIPSTICK OF ANTIFUNGAL AGENT
Bhupendra Gopalbhai Prajapati, Ganpat University, Shree S.K.Patel College of Pharmaceutical Education and Research, India
Title : Sol-gel, phase inversion precipitation and microfluidic systems for controlled delivery of pharmaceuticals and bioactive compounds in nutraceuticals and nano nutraceuticals
Sandile Phinda Songca, University of KwaZulu-Natal, South Africa
Title : The e?ects of Anethum graveolens (dill) supplementation on lipid profile and glycemic control: A systematic review and meta-analysis of randomized controlled trials
Seyed Mohammad Mousavi, Tehran University of Medical Sciences, Tehran, Iran., Iran (Islamic Republic of)